by Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, DNDi Clinical Team, Cressey TR, Punyawudho B, Musiime V, LIVING Study Team. Journal of the Pediatric Infectious Diseases Society 2023, 12(11). doi: 10.1093/jpids/piad082
Summary: There is limited information about the pharmacokinetics of abacavir, taken as part of a fixed-dose combination according to WHO weight bands, in African children living with HIV who weigh less than 14 kg. The authors of this manuscript developed a population pharmacokinetic model to evaluate abacavir exposure across different WHO weight bands, using samples from 387 children enrolled the LIVING study in Kenya and Uganda who were treated with abacavir/lamivudine dispersible tablets (60/30 mg). They concluded that lowering the abacavir dosage to 30 mg twice-daily or 60 mg once-daily for children weighing 3-5.9 kg would increase the proportion of children within the target exposure range and provide comparable exposure.
